keloid
Conditions
Interventions
Group A:Group A: 2940nm Fractional Er:YAG Laser combined with Halometasone and Triclosan Cream
Group B:Group B: 2940nm Fractional Er:YAG Laser combined with Compound
Sponsors
The First Affiliated Hospital of Xiamen University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. meets the clinical diagnostic criteria for keloid, i.e. keloid exceeding the original extent of injury, persistent growth, hard texture, smooth surface, reddish or dark red colour; 2. Be between the ages of 18 - 60 years old; 3. have not received any scar-related treatment (including laser, cryotherapy, drug injection, topical medication, surgery, etc.) in the past 3 months; 4. Volunteer to participate in this study, fully understand the study process and potential risks, and sign a written informed consent form; 5. Be able to cooperate with the 12-week treatment and the subsequent 6-month follow-up, and ensure that they will return to the clinic on time;
Exclusion criteria
Exclusion criteria: 1. have active lesions such as skin infections and ulcers at the keloid site; 2. Suffering from serious heart, liver, kidney and other important organ diseases; 3. Allergic to halometasone triclosan cream, compound betamethasone topical injection or laser treatment; 4. Have received other scar treatments within the last 3 months; 5. Pregnant or lactating women; 6. Subjects who refuse to use effective contraception during the study and for 3 months after the last treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pigmentation; | — |
Secondary
| Measure | Time frame |
|---|---|
| pain;Patient and Observer Scar Assessmen; | — |
Countries
China
Contacts
Public ContactZhang Qiguo
The First Affiliated Hospital of Xiamen University
Outcome results
None listed